Karyopharm begins Phase II trial of hormone refractory prostate cancer drug Selinexor
US-based clinical-stage pharmaceutical firm Karyopharm Therapeutics has started a Phase II trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) for treatment of patients with metastatic hormone-refractory…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Hormone Refractory Prostate Cancer | Hormones | Oral Cancer | Pharmaceuticals | Prostate Cancer